eMedicine Specialties > Dermatology > Diseases of the Vessels

Mondor Disease: Treatment & Medication

Author: Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Medicine, Professor of Pediatrics, Professor of Pathology, Professor of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Coauthor(s): Matthew J Trovato, MD, Staff Physician, Department of Dermatology, UMDNJ-New Jersey Medical School
Contributor Information and Disclosures

Updated: Apr 30, 2008

Treatment

Medical Care

Treatment is entirely symptomatic.

  • Hot, wet dressings and anodynes may be used for pain relief.
  • The use of modalities such as enzymes, corticosteroids, antibiotics, vaccines, and anticoagulants has been studied, although none has been proven to hasten the resolution of the pathologic process.
  • The major benefit that the physician can provide is reassurance.

Surgical Care

Treatment is symptomatic because, to date, the disease has proved to be benign and self-limited.

Medication

Nonsteroidal anti-inflammatory agents (NSAIDs) are used for symptomatic relief. Indomethacin is a good choice.

Nonsteroidal anti-inflammatory drugs

These agents have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known, but they may inhibit cyclo-oxygenase activity and prostaglandin synthesis. Other mechanisms may include inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell membrane functions.


Indomethacin (Indocin)

Potent inhibitor of cyclo-oxygenase, which may decrease the local production of arachidonic acid–derived chemotactic factors for eosinophils present in sebum.

Adult

50 mg PO tid pc; taper as symptoms resolve

Pediatric

<14 years: Not established
>14 years: Administer as in adults

Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when patient is taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of MTX toxicity; phenytoin levels may be increased when administered concurrently

Documented hypersensitivity; GI bleeding; renal insufficiency

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Category D in third trimester of pregnancy (may cause closure of ductus arteriosus during the third trimester of pregnancy); may mask signs of infection; may cause fluid retention, peripheral edema, and deterioration of circulatory hemodynamics; can inhibit platelet aggregation and prolong bleeding time; liver and kidney damage may occur (rare)


Aspirin (Anacin, Ascriptin, Bayer Aspirin, Bayer Buffered Aspirin)

Treats mild to moderate pain. Inhibits prostaglandin synthesis, which prevents formation of platelet-aggregating thromboxane A2.

Adult

325-650 mg PO q4-6h; not to exceed 4 g/d

Pediatric

10-15 mg/kg/dose PO q4-6h; not to exceed 60-80 mg/kg/d

Effects may decrease with antacids and urinary alkalinizers; corticosteroids decrease salicylate serum levels; additive hypoprothrombinemic effects and increased bleeding time may occur with coadministration of anticoagulants; may antagonize uricosuric effects of probenecid and increase toxicity of phenytoin and valproic acid; doses >2 g/d may potentiate glucose-lowering effect of sulfonylurea drugs

Documented hypersensitivity; liver damage; hypoprothrombinemia; vitamin K deficiency; bleeding disorders; asthma; because of association of aspirin with Reye syndrome, do not use in children (<16 y) with flu

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Category D in third trimester of pregnancy; may cause transient decrease in renal function and aggravate chronic kidney disease; avoid use in patients with severe anemia, in those with a history of blood coagulation defects, or in those taking anticoagulants

More on Mondor Disease

Overview: Mondor Disease
Differential Diagnoses & Workup: Mondor Disease
Treatment & Medication: Mondor Disease
Follow-up: Mondor Disease
Multimedia: Mondor Disease
References
[ CLOSE WINDOW ]

References

  1. Thalhammer C, Aschwanden M. [Mondor's disease]. Dtsch Med Wochenschr. Feb 16 2007;132(7):325-6. [Medline].

  2. Al-Mwalad M, Loertzer H, Wicht A, Fornara P. Subcutaneous penile vein thrombosis (Penile Mondor's Disease): pathogenesis, diagnosis, and therapy. Urology. Mar 2006;67(3):586-8. [Medline].

  3. Hogan GF. Mondor's disease. Arch Intern Med. Jun 1964;113:881-5. [Medline].

  4. Weinstein EC. Mondor's disease. West J Med. Jul 1975;123(1):56-7. [Medline].

  5. Herrmann JB. Thrombophlebitis of breast and contiguous thoracicoabdominal wall (Mondor's disease). N Y State J Med. Dec 15 1966;66(24):3146-52. [Medline].

  6. Loos B, Horch RE. Mondor's disease after breast reduction surgery. Plast Reconstr Surg. Jun 2006;117(7):129e-132e. [Medline].

  7. Talhari C, Mang R, Megahed M, Ruzicka T, Stege H. Mondor disease associated with physical strain: report of 2 cases. Arch Dermatol. Jun 2005;141(6):800-1. [Medline].

  8. Oldfield MC. Mondor's disease. A superficial phlebitis of the breast. Lancet. May 12 1962;1:994-6. [Medline].

  9. Feller N. [Mondor's disease.]. Dapim Refuiim. Aug 1962;21:423-5. [Medline].

  10. Bauer-Hack K. [Contribution to Mondor's disease.]. Med Welt. Oct 13 1962;41:2152-6. [Medline].

  11. Losanoff JE, Basson MD, Salwen WA, Sochaki P. Mondor's disease mimicking a Spigelian hernia. Hernia. Jan 9 2008;[Medline].

  12. Dicuio M, Pomara G, Ales V, Fabris FM, Dahlstrand C, Morelli G. Doppler ultrasonography in a young patient with penile Mondor's disease. Arch Ital Urol Androl. Mar 2005;77(1):58-9. [Medline].

  13. Bircher J, Schirger A, Clagett OT, Harrison EG Jr. Mondor's disease: a vascular rarity. Mayo Clin Proc. Nov 21 1962;37:651-6. [Medline].

  14. Guerri G. [Histopathology and significance of cord formations on the anterolateral chest wall (Mondor's disease and syndrome).]. Arch De Vecchi Anat Patol. Oct 1960;33:829-57. [Medline].

  15. Holle-Robatsch S, Fink AM, Schubert C, Steiner A, Partsch H. [Mondor phlebitis associated with hepatitis C]. Vasa. Nov 2001;30(4):297-8. [Medline].

  16. Luis Rodríguez-Peralto J, Carrillo R, Rosales B, Rodríguez-Gil Y. Superficial thrombophlebitis. Semin Cutan Med Surg. Jun 2007;26(2):71-6. [Medline].

  17. Mayor M, Buron I, de Mora JC, Lazaro TE, Hernandez-Cano N, Rubio FA, et al. Mondor's disease. Int J Dermatol. Dec 2000;39(12):922-5. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

Mondor's disease, Mondor phlebitis, superficial thrombophlebitis of the chest wall

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Medicine, Professor of Pediatrics, Professor of Pathology, Professor of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi
Disclosure: Nothing to disclose.

Coauthor(s)

Matthew J Trovato, MD, Staff Physician, Department of Dermatology, UMDNJ-New Jersey Medical School
Matthew J Trovato, MD is a member of the following medical societies: Alpha Omega Alpha
Disclosure: Nothing to disclose.

Medical Editor

Julie C Harper, MD, Assistant Program Director, Assistant Professor, Department of Dermatology, University of Alabama at Birmingham
Julie C Harper, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

Pharmacy Editor

David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: 3M Pharmaceutical Grant/research funds Other; Graceway Pharmaceuticals Grant/research funds Other

Managing Editor

Christen M Mowad, MD, Associate Professor, Department of Dermatology, Geisinger Medical Center
Christen M Mowad, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Phi Beta Kappa
Disclosure: Nothing to disclose.

CME Editor

Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University
Catherine Quirk, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.